A protein called SAP is thought to be involved in the development of Alzheimer's disease. Researchers at University College, London tried out a new drug called CPHPC on five Alzheimer's patients over a three-month period and found it made SAP disappear. However, it is too soon to know whether the removal of SAP would lead to clinical benefits for patients and there have been many false dawns in Alzheimer's research before.
You can find out more about this research at
http://uk.reuters.com/article/healthNews/idUKTRE53D1B820090414?feedType=RSS&feedName=healthNews
-
Posts
1 comment:
This type of research is exactly why studies are so important.
It is important for patients and families affected by diseases such as Alzheimer's to consider participating in clinical studies.
One such study for Alzheimer’s is the ICARA (Bapi) study (www.icarastudy.com), whose goal is to explore if an investigational drug, called Bapineuzumab, can help slow the progression of Alzheimer's Disease. Current therapies for Alzheimer's treat the symptoms associated with it, not the disease itself.
Post a Comment